| Rates of pneumococcal disease in adults with chronic medical conditions KM Shea, J Edelsberg, D Weycker, RA Farkouh, DR Strutton, SI Pelton Open forum infectious diseases 1 (1), ofu024, 2014 | 319 | 2014 |
| Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions D Weycker, RA Farkouh, DR Strutton, J Edelsberg, KM Shea, SI Pelton BMC health services research 16, 1-10, 2016 | 94 | 2016 |
| Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine SI Pelton, D Weycker, RA Farkouh, DR Strutton, KM Shea, J Edelsberg Clinical infectious diseases 59 (5), 615-623, 2014 | 83 | 2014 |
| Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands DR Strutton, RA Farkouh, SR Earnshaw, S Hwang, U Theidel, ... Journal of Infection 64 (1), 54-67, 2012 | 73 | 2012 |
| Cost-effectiveness of a 10-versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden RM Klok, RM Lindkvist, M Ekelund, RA Farkouh, DR Strutton Clinical therapeutics 35 (2), 119-134, 2013 | 64 | 2013 |
| Cost-effectiveness of 2+ 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada SR Earnshaw, CL McDade, G Zanotti, RA Farkouh, D Strutton BMC infectious diseases 12, 1-13, 2012 | 64 | 2012 |
| Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV TL Kauf, RA Farkouh, SR Earnshaw, ME Watson, P Maroudas, ... Pharmacoeconomics 28, 1025-1039, 2010 | 58 | 2010 |
| Rates of pneumonia among children and adults with chronic medical conditions in Germany SI Pelton, KM Shea, RA Farkouh, DR Strutton, S Braun, C Jacob, R Klok, ... BMC infectious diseases 15, 1-8, 2015 | 54 | 2015 |
| Rethinking risk for pneumococcal disease in adults: the role of risk stacking SI Pelton, KM Shea, D Weycker, RA Farkouh, DR Strutton, J Edelsberg Open forum infectious diseases 2 (1), ofv020, 2015 | 39 | 2015 |
| Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada M Wilson, M Wasserman, T Jadavi, M Postma, MC Breton, F Peloquin, ... Infectious diseases and therapy 7, 353-371, 2018 | 38 | 2018 |
| Economic evaluation of meningococcal vaccines: considerations for the future H Christensen, H Al-Janabi, P Levy, MJ Postma, DE Bloom, P Landa, ... The European Journal of Health Economics 21, 297-309, 2020 | 36 | 2020 |
| Twenty-year public health impact of 7-and 13-valent pneumococcal conjugate vaccines in US children M Wasserman, R Chapman, R Lapidot, K Sutton, D Dillon-Murphy, ... Emerging infectious diseases 27 (6), 1627, 2021 | 33 | 2021 |
| Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine M Wasserman, HL Sings, D Jones, S Pugh, M Moffatt, R Farkouh Expert review of vaccines 17 (1), 71-78, 2018 | 30 | 2018 |
| Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines E Mucino-Ortega, JF Mould-Quevedo, R Farkouh, D Strutton Value in Health: the Journal of the International Society for …, 2011 | 30 | 2011 |
| Cost–effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions RA Farkouh, RM Klok, MJ Postma, CS Roberts, DR Strutton Expert review of vaccines 11 (10), 1235-1247, 2012 | 25 | 2012 |
| Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States L Huang, M Wasserman, L Grant, R Farkouh, V Snow, A Arguedas, ... Vaccine 40 (33), 4700-4708, 2022 | 24 | 2022 |
| Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China K Shen, M Wasserman, D Liu, YH Yang, J Yang, GF Guzauskas, ... PLoS One 13 (7), e0201245, 2018 | 24 | 2018 |
| Potential reduction in neural tube defects associated with use of Metafolin-fortified oral contraceptives in the United States TN Taylor, RA Farkouh, JB Graham, A Colligs, M Lindemann, R Lynen, ... American journal of obstetrics and gynecology 205 (5), 460. e1-460. e8, 2011 | 23 | 2011 |
| Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico M Wasserman, MG Palacios, AG Grajales, FB Baez/Revueltas, M Wilson, ... Human Vaccines & Immunotherapeutics 15 (3), 560-569, 2019 | 21 | 2019 |
| Clinical and economic burden of pneumococcal disease due to serotypes contained in current and investigational pneumococcal conjugate vaccines in children under five years of age MD Wasserman, J Perdrizet, L Grant, K Hayford, S Singh, P Saharia, ... Infectious Diseases and Therapy 10, 2701-2720, 2021 | 20 | 2021 |
